Nurix Therapeutics(NRIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NRIX Nurix Therapeutics

Post-Mkt 12-11 19:40:32 EST

19.07

-0.54

-2.75%

盘后19.00

-0.07-0.37%

18:43 EST

High19.95	Low19.02	Vol1.42M
Open19.63	D1 Closing19.61	Amplitude4.74%
Mkt Cap1.93B	Tradable Cap1.65B	Total Shares101.37M
T/O27.44M	T/O Rate1.65%	Tradable Shares86.36M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NRIX","market":"US","secType":"STK","nameCN":"Nurix Therapeutics","latestPrice":19.07,"timestamp":1765486800000,"preClose":19.61,"halted":0,"volume":1420897,"hourTrading":{"tag":"盘后","latestPrice":19,"preClose":19.07,"latestTime":"18:43 EST","volume":115040,"amount":2193882.9743999997,"timestamp":1765496591393},"delay":0,"floatShares":86361800,"shares":101369235,"eps":-2.967657,"marketStatus":"Post-Mkt","change":-0.54,"latestTime":"12-11 19:40:32 EST","open":19.63,"high":19.95,"low":19.02,"amount":27439192.044872,"amplitude":0.047425,"askPrice":19.65,"askSize":100,"bidPrice":19,"bidSize":30,"shortable":3,"etf":0,"ttmEps":-2.967657,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1765501200000},"marketStatusCode":4,"adr":0,"listingDate":1595563200000,"exchange":"NASDAQ","adjPreClose":19.61,"preHourTrading":{"tag":"盘前","latestPrice":19.47,"preClose":19.61,"latestTime":"09:26 EST","volume":850,"amount":16711.5899,"timestamp":1765463188791},"postHourTrading":{"tag":"盘后","latestPrice":19,"preClose":19.07,"latestTime":"18:43 EST","volume":115040,"amount":2193882.9743999997,"timestamp":1765496591393},"volumeRatio":0.51363,"impliedVol":0.9114,"impliedVolPercentile":0.648},"requestUrl":"/m/hq/s/NRIX/tweets","defaultTab":"tweets","newsList":[{"id":"2590587762","title":"Mizuho Adjusts Price Target on Nurix Therapeutics to $30 From $24, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2590587762","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590587762?lang=en_us&edition=fundamental","pubTime":"2025-12-10 21:29","pubTimestamp":1765373348,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics (NRIX) has an average rating of buy and mean price target of $27.88, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MFG","NRIX"],"gpt_icon":0},{"id":"2590586090","title":"Nurix Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $31 From $28","url":"https://stock-news.laohu8.com/highlight/detail?id=2590586090","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590586090?lang=en_us&edition=fundamental","pubTime":"2025-12-10 19:10","pubTimestamp":1765365029,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nAZN4RCRIP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NRIX"],"gpt_icon":0},{"id":"2590164326","title":"Nurix Therapeutics Is Maintained at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2590164326","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590164326?lang=en_us&edition=fundamental","pubTime":"2025-12-10 03:02","pubTimestamp":1765306920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRIX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 09, 2025 14:02 ET (19:02 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX"],"gpt_icon":0},{"id":"2590311390","title":"Nurix Therapeutics Inc : Btig Raises Target Price to $30 From $27","url":"https://stock-news.laohu8.com/highlight/detail?id=2590311390","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590311390?lang=en_us&edition=fundamental","pubTime":"2025-12-09 14:45","pubTimestamp":1765262712,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XE1RO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRIX","BK4139"],"gpt_icon":0},{"id":"2590368328","title":"BUZZ-U.S. STOCKS ON THE MOVE-Five Below, Boeing, Instacart","url":"https://stock-news.laohu8.com/highlight/detail?id=2590368328","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590368328?lang=en_us&edition=fundamental","pubTime":"2025-12-09 02:45","pubTimestamp":1765219558,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Five Below, Boeing, InstacartEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: http","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nL6N3XE0MP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FCX","OCUL","CFLT","DYN","INCY","SCCO","COMP","OMF","APD","BKR","CRH","GM","WYNN","KYMR","MMM","NRIX","AGIO","NEE","FIVE","ROK","COP","JEF","XOM","CVX","ALB","TPL","RIOT","WBD","FULC","GPCR","LNG","EXE","APA","FANG","EOG","USCB","AR","LEN","HUT","ACLX"],"gpt_icon":1},{"id":"2590660352","title":"Nurix Therapeutics Up Over 18%, on Pace for Larget Percent Increase Since June 2024 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2590660352","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590660352?lang=en_us&edition=fundamental","pubTime":"2025-12-09 00:17","pubTimestamp":1765210620,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics, Inc.  is currently at $21.44, up $3.36 or 18.55%. --Would be highest close since Dec. 10, 2024, when it closed at $22.06. --On pace for largest percent increase since June 18, 2024, when it rose 20.6%. --Currently up four consecutive days; up 31.16% over this period. --Longest winning streak since Nov. 24, 2025, when it rose for four straight trading days. --Down 57.26% from its all-time closing high of $50.17 on Jan. 19, 2021. --Up 3.8% from 52 weeks ago , when it closed at $20.66. --Up 160.25% from its 52-week closing low of $8.24 on Sept. 23, 2025. --Traded as high as $22.50; highest intraday level since Dec. 11, 2024, when it hit $22.95. --Up 24.38% at today's intraday high; largest intraday percent increase since April 9, 2024, when it rose as much as 26.88%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRIX"],"gpt_icon":0},{"id":"2589351532","title":"Nurix Therapeutics Stock Rises on Positive Trial Data for Blood Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2589351532","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589351532?lang=en_us&edition=fundamental","pubTime":"2025-12-08 22:48","pubTimestamp":1765205280,"startTime":"0","endTime":"0","summary":"Shares of Nurix Therapeutics rose after the company reported positive trial data for a potential treatment for a type of blood cancer.The stock rose 22% to $22.01 on Monday. Shares are up 13% this year.The biopharmaceutical company said its Bexobrutideg showed an objective response rate of 75%, including three very good partial responses, in heavily pre-treated Waldenstrm macroglobulinemia patients in a recent trial.The data demonstrates durable and deepening responses with longer time on treatment, and shows that the drug was well tolerated, consistent with previous disclosures, Chief Medical Officer Paula O'Connor said.The drug's encouraging efficacy and favorable tolerability support continued development, the company said.Waldenstrm macroglobulinemia is a rare cancer that affects white blood cells.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"gpt_icon":0},{"id":"2589359222","title":"Nurix Therapeutics Shares Jump to Near One-Year High After Early Stage Blood Cancer Drug Trial Data, Last up 20.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589359222","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589359222?lang=en_us&edition=fundamental","pubTime":"2025-12-08 22:32","pubTimestamp":1765204327,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nL4N3XE16A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NRIX"],"gpt_icon":0},{"id":"2589451356","title":"BUZZ-Nurix Therapeutics climbs after blood cancer drug trial data","url":"https://stock-news.laohu8.com/highlight/detail?id=2589451356","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589451356?lang=en_us&edition=fundamental","pubTime":"2025-12-08 22:07","pubTimestamp":1765202850,"startTime":"0","endTime":"0","summary":"BUZZ-Nurix Therapeutics climbs after blood cancer drug trial data** Shares of drug developer Nurix Therapeutics NRIX.O jump 19.6% to $21.63 premarket** NRIX said 75% of patients demonstrated objective","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nL6N3XE0RZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"gpt_icon":0},{"id":"2589353249","title":"Nurix Therapeutics Shares Jump 16.2% Premarket After Early Stage Cancer Drug Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2589353249","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589353249?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:18","pubTimestamp":1765199907,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nL4N3XE0Z0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRIX","BK4139"],"gpt_icon":0},{"id":"2589353672","title":"BRIEF-Nurix Therapeutics Presents New Data From The Phase 1 Trial Of Bexobrutideg In Waldenström Macroglobulinemia At The 67th American Society Of Hematology Annual Meeting And Exposition","url":"https://stock-news.laohu8.com/highlight/detail?id=2589353672","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589353672?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:07","pubTimestamp":1765199238,"startTime":"0","endTime":"0","summary":"BRIEF-Nurix Therapeutics Presents New Data From The Phase 1 Trial Of Bexobrutideg In Waldenstrm Macroglobulinemia At The 67th American Society Of Hematology Annual Meeting And ExpositionDec 8 (Reuters","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nTUABJG6V8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"gpt_icon":0},{"id":"2589538423","title":"Nurix Therapeutics Presents New Data From the Phase 1 Trial of Bexobrutideg (Nx-5948) in WaldenstrÖM Macroglobulinemia at the 67TH American Society of Hematology (Ash) Annual Meeting and Exposition","url":"https://stock-news.laohu8.com/highlight/detail?id=2589538423","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589538423?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:00","pubTimestamp":1765198802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nTUABJG6V8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRIX","BK4139"],"gpt_icon":0},{"id":"2589302813","title":"Nurix Therapeutics Price Target Maintained With a $26.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2589302813","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589302813?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:24","pubTimestamp":1765196640,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRIX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 08, 2025 07:24 ET (12:24 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX"],"gpt_icon":0},{"id":"2589874507","title":"Nurix Therapeutics (NRIX): Valuation Check After New NX-5948 Phase 1a/1b Data at ASH 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2589874507","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589874507?lang=en_us&edition=fundamental","pubTime":"2025-12-07 18:13","pubTimestamp":1765102392,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics (NRIX) is back in the spotlight after unveiling fresh Phase 1a/1b data on its BTK degrader NX 5948 at the ASH 2025 meeting, reinforcing a 600 mg dose for Phase 2.\nSee our latest analysis for Nurix Therapeutics.\nThe ASH update caps a sharp reversal in sentiment for Nurix, with a roughly 87% 3 month share price return and a still negative 1 year total shareholder return. This suggests that momentum is rebuilding after a tough stretch.\nIf this kind of clinical inflection point...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/nurix-therapeutics-nrix-valuation-check-after-new-nx-5948-ph","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/nurix-therapeutics-nrix-valuation-check-after-new-nx-5948-ph","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NX","NRIX","ASH","LU2065732104.USD","BK4086","BK4109","BK4139","LU2463526074.USD"],"gpt_icon":0},{"id":"2589826153","title":"Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition","url":"https://stock-news.laohu8.com/highlight/detail?id=2589826153","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589826153?lang=en_us&edition=fundamental","pubTime":"2025-12-06 22:30","pubTimestamp":1765031400,"startTime":"0","endTime":"0","summary":"Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression free survival (PFS) of 22.1 months across all doses tested Emerging data","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/06/3201064/0/en/Nurix-Therapeutics-Presents-New-Data-Demonstrating-Durable-Deepening-Responses-in-Phase-1-Trial-of-Bexobrutideg-NX-5948-in-Patients-with-Relapsed-or-Refractory-Chronic-Lymphocytic-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","NX","ASH","AFG"],"gpt_icon":0},{"id":"2588316722","title":"Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition","url":"https://stock-news.laohu8.com/highlight/detail?id=2588316722","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588316722?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590400,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, Dec.  01, 2025  (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ta","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/01/3196838/0/en/Nurix-Therapeutics-Announces-Webcast-to-Review-New-and-Updated-Data-from-the-Phase-1-Clinical-Trial-of-BTK-Degrader-Bexobrutideg-NX-5948-To-Be-Presented-at-the-67th-American-Societ.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASH","LU2413666699.HKD","LU1923621640.USD","LU1585245621.USD","BK4117","LU0289739343.SGD","LU2298064838.USD","LU2413666426.HKD","LU2238339852.HKD","LU1989772923.USD","AFG","LU1974910355.USD","LU0057025933.USD","BK4566","LU2125910336.SGD","BK4120","BK4533","LU0069063385.USD","LU1939255532.USD","LU2308191902.HKD","BK4139","BK4107","NRIX","LU2065732104.USD","WM","LU1623119135.USD","LU0472753341.HKD","LU1712237335.SGD","BK4086","LU2463526074.USD","LU2106854487.HKD","BK4109","LU1430594728.SGD","LU2125910179.SGD","LU2362541513.USD","BK4588","LU0289960550.SGD","LU0124676726.USD","LU2089279066.USD","BK4585","LU1892829315.USD","LU0689626769.HKD","LU2355687059.USD","NX","BK4534","LU2211814178.USD","LU0511384066.AUD","LU1989772840.SGD","LU0175139822.USD","LU2362541273.HKD"],"gpt_icon":0},{"id":"2586406415","title":"Nurix Therapeutics Chief Legal Officer Christine Ring Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586406415","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586406415?lang=en_us&edition=fundamental","pubTime":"2025-11-25 07:06","pubTimestamp":1764025617,"startTime":"0","endTime":"0","summary":"Christine Ring, Chief Legal Officer of Nurix Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nurix Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 24, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL6M49TT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Nurix Therapeutics Chief Legal Officer Christine Ring Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRIX"],"gpt_icon":0},{"id":"2586361494","title":"Nurix Therapeutics Coverage Assumed by Truist Securities at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2586361494","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586361494?lang=en_us&edition=fundamental","pubTime":"2025-11-25 02:23","pubTimestamp":1764008580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRIX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 24, 2025 13:23 ET (18:23 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"gpt_icon":0},{"id":"2585629044","title":"Nurix Therapeutics Inc : Truist Securities Raises Target Price to $30 From $23","url":"https://stock-news.laohu8.com/highlight/detail?id=2585629044","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585629044?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:07","pubTimestamp":1763989663,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nFWN3X00H4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRIX","BK4139"],"gpt_icon":0},{"id":"2585666462","title":"Nurix Therapeutics (NRIX) Gets a Buy from Truist Financial","url":"https://stock-news.laohu8.com/highlight/detail?id=2585666462","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585666462?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:46","pubTimestamp":1763988380,"startTime":"0","endTime":"0","summary":"In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Nurix Therapeutics, with a price target of $30.00...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/nurix-therapeutics-nrix-gets-a-buy-from-truist-financial-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/nurix-therapeutics-nrix-gets-a-buy-from-truist-financial-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRIX","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nurixtx.com","stockEarnings":[{"period":"1week","weight":0.1652},{"period":"1month","weight":0.6008},{"period":"3month","weight":1.1315},{"period":"6month","weight":0.6438},{"period":"1year","weight":-0.1111},{"period":"ytd","weight":0.0409}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing DeTIL-0255, a drug-enhanced investigational cell therapy product that uses NX-0255 ex vivo to enhance tumor infiltrating lymphocytes propagation and phenotypic characteristics. The company has a strategic collaboration agreement with Gilead Sciences, Inc. to discover, develop, and commercialize a pipeline of protein degradation drugs for patients with cancer and other challenging diseases; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.063877},{"month":2,"riseRate":0.2,"avgChangeRate":-0.007659},{"month":3,"riseRate":0.2,"avgChangeRate":-0.071924},{"month":4,"riseRate":0.4,"avgChangeRate":-0.043438},{"month":5,"riseRate":0.4,"avgChangeRate":-0.000824},{"month":6,"riseRate":0.6,"avgChangeRate":0.118065},{"month":7,"riseRate":0.6,"avgChangeRate":0.085462},{"month":8,"riseRate":0.5,"avgChangeRate":0.016029},{"month":9,"riseRate":0.166667,"avgChangeRate":0.009437},{"month":10,"riseRate":0.5,"avgChangeRate":0.003905},{"month":11,"riseRate":0.5,"avgChangeRate":0.149774},{"month":12,"riseRate":0.5,"avgChangeRate":0.047101}],"exchange":"NASDAQ","name":"Nurix Therapeutics","nameEN":"Nurix Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nurix Therapeutics(NRIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nurix Therapeutics(NRIX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nurix Therapeutics,NRIX,Nurix Therapeutics股票,Nurix Therapeutics股票老虎,Nurix Therapeutics股票老虎国际,Nurix Therapeutics行情,Nurix Therapeutics股票行情,Nurix Therapeutics股价,Nurix Therapeutics股市,Nurix Therapeutics股票价格,Nurix Therapeutics股票交易,Nurix Therapeutics股票购买,Nurix Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nurix Therapeutics(NRIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nurix Therapeutics(NRIX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction